Kymera un­veils ‘ex­cep­tion­al’ Phase 1 da­ta for its Dupix­ent-in-a-pill pro­gram

The small biotech Kymera Ther­a­peu­tics be­lieves it could have a po­ten­tial oral com­peti­tor to the megablock­buster Dupix­ent.

There’s a long road ahead for Kymera’s im­munol­o­gy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER